DRL-17822 is a selective cholesteryl ester transfer protein (CETP) inhibitor. DRL-17822 increases high-density lipoprotein levels. The exposure of DRL-17822 nanocrystal formulation increases significantly after a high-fat breakfast. The exposure of DRL-17822 in the fasted state is higher than that of its nanocrystal formulation. DRL-17822 can be used in the research of type II hyperlipidemia and atherosclerotic cardiovascular disease.

DPP9-IN-2 is a selective, potent and orally active inhibitor of Dipeptidyl Peptidase 9 (DPP9 ) with an IC50 of 12.9 nM. DPP9-IN-2 shows a SI of 59 over DPP8, and shows no significant inhibitory activity against related peptidases including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 can induce cancer cells pyroptosis and has weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitor. DPP9-IN-2 can be used for the researches of cance rand infection.

DPAP is a p-ERK1/2 inhibitor with an IC50 of 7.85 μM against p-ERK1/2. DPAP inhibits the expression of p-MEK1/2 and disrupts the Ras-ERK signaling pathway. DPAP inhibits the expression of COX-2 in nerve cells. DPAP damages DNA and mitochondria, induces Apoptosis via the mitochondrial pathway, and upregulates PD-L1. DPAP inhibits melanoma metastasis and angiogenesis, and inactivates spinal microglia and astrocytes. DPAP exhibits anti-melanoma activity and can be combined with anti-PD-1 monoclonal antibodies to modify anti-tumor effects. DPAP is applicable for the research of melanoma.

Doxapram (hydrochloride) is a ventilatory stimulant. Doxapram (hydrochloride) inhibits TASK Tandem Pore (K2P) potassium channel function. Doxapram (hydrochloride) inhibits TASK-1 and TASK-3 with an EC50 values of 410 and 37 nM, respectively. Doxapram (hydrochloride) inhibits TASK-1/TASK-3 heterodimeric channel function with an EC50 value of 9 μM. Doxapram (hydrochloride) can be studied in research on apnea in preterm infants.

Dotarizine is a novel Piperazine derivative and antimigraine agent. Dotarizine exhibits Ca2+ channel blocking properties. Dotarizine decreases the release of lactate dehydrogenase. Dotarizine shows 5-HT receptor blocking effect.

DOT1L808 is a potent and highly selective DOT1L PROTAC degrader with a DC50 value of 5 nM. DOT1L808 can promote the ubiquitination and degradation of DOT1L. DOT1L808 exhibits antitumor activity in an orthotopic leukemia model. (Pink: DOT1L ligand ; Blue: VHL ligand ; Black: linker).

Domitroban is a thromboxane A2 receptor (TBXA2R) antagonist. Domitroban can inhibit platelet aggregation. Domitroban can be used for the research of cardiovascular disease, such as thrombosis.

Docosanoyl-CoA is a nucleoside metabolite.

DNMT-IN-6 is a DNA methyltransferase inhibitor with activity against DNMT1, DNMT3A, and DNMT3B. DNMT-IN-6 drives demethylation, and restores TMS1 tumor suppressor gene expression. DNMT-IN-6 induces apoptosis, causes G2/M phase arrest, disrupts mitochondrial integrity, and activates the intrinsic caspase cascade (3/7/9). DNMT-IN-6 inhibits tumor growth, and improves survival in xenograft models. DNMT-IN-6 can be used for the research of cancer, such as diffuse large B-cell lymphoma.

DNMT/HDAC-IN-2 (Compound Y7) is a DNMT and HDAC inhibitor with IC50 values for DNMT1, HDAC1, and HDAC6 of 365, 0.2, and 8.91 nM respectively. DNMT/HDAC-IN-2 inhibits the proliferation of breast cancer cells. DNMT/HDAC-IN-2 significantly reduces tumor growth in xenografts and transgenic breast cancer mouse models. DNMT/HDAC-IN-2 can be used for the study of breast cancer.

DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8+ T cells in tumor tissues through synergistic action with anti-PD-L1 monoclonal antibody. DNA-PK-IN-16 is applicable for cancer research.

DNA-PK/HDAC6-IN-1 is a selcetive and orally active dual DNA-PK and HDAC6 inhibitor with IC50 values of 84.2 and 64.8 nM. DNA-PK/HDAC6-IN-1 suppresses cancer cells proliferation, induces cancer cell cycle G2/M arrest, apoptosis, and decreases the mitochondrial membrane potential. DNA-PK/HDAC6-IN-1 induces DNA damage and elevates γ-H2AX levels. DNA-PK/HDAC6-IN-1 exhibits antitumor efficacy in AML animal mouse model. DNA-PK/HDAC6-IN-1 can be used for the research of acute myeloid leukemia.

DNA-GAGA is a slow substrate for Ricin toxin A-chain (RTA). RTA depurinates a single adenylate on a GAGA stem-loop region of eukaryotic 28S RNA, making it a potent toxin.

DM245 is an EPAC1 activator and STAT3 phosphorylation inhibitor with a target pIC50 of 4.801. DM245 activates EPAC1 to increase Rap1-GTP levels, with no activation of EPAC2 or PKA. DM245 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM245 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing αSMA and Collagen I levels. DM245 exhibits minimal cytotoxicity in normal human lung fibroblasts, with negligible loss of intact nuclei after 72 h exposure.

DM243 is an EPAC1 activator and STAT3 modulator with an pIC50 of 4.769. DM243 increases GTP-bound Rap1 levels in EPAC1-expressing cells, with no activation of EPAC2 or PKA. DM243 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM243 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing α-smooth muscle actin and Collagen I levels in lung fibroblasts. DM243 exhibits minimal cytotoxicity in normal human lung fibroblasts.

DM175 is a partial agonist of FXR. DM175 binds to the ligand-binding domain of FXR and induces the outward movement of Trp454.

DM-1157 is an orally active asymmetric bisquinoline heme inhibitor with a IC50 of 1.6 μM and a Kd of 1.7 μM. DM-1157 binds to heme dimers in solution, inhibits β-hematin formation, suppresses hemozoin formation in the digestive vacuole of Plasmodium falciparum, accumulates in the digestive vacuole of Plasmodium falciparum, induces enlargement of the digestive vacuole of Plasmodium falciparum, and inhibits the growth of Chloroquine-sensitive and resistant Plasmodium falciparum strains. DM-1157 can be used for the research of malaria and Plasmodium falciparum-type malaria.

DLK-IN-2 is a selective inhibitor of DLK and neuroprotective agent. DLK-IN-2 shows no significant inhibition against CYPs 3A4, 2D6 and 2C9. DLK-IN-2 inhibits acute axonal palmitoylation of DLK, blocks DLK-dependent pro-degenerative axon-to-soma retrograde signaling and suppresses c-Jun phosphorylation. DLK-IN-2 can be used for the mechanistic study of neurodegenerative diseases.

Dipotassium [2,2'-biquinoline]-4,4'-dicarboxylate is a metal-organic framework (MOF).

Dioxyindolylalanine, a tryptophan analogue, is an inhibitor of tryptophan synthase.

Dimovarsen, an oligonucleotide, is a micro RNA-132 inhibitsor, and can be use for the study of heart failure.

Dimethyl 3-hydroxyphthalate-amido-C4-N3 is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.

Dimefluthrin is an insecticide. Dimefluthrin exhibits contact toxicity against large red imported fire ant workers. Dimefluthrin undergoes horizontal transfer among red imported fire ant workers, causing secondary mortality in recipient workers. Dimefluthrin is a neurodevelopmental toxicant, which can reduces acetylcholinesterase activity, impairing neurotransmitter.

DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with KD values of 7.7 μM and 12.0 μM for NR4A1 and NR4A2, respectively. DIM-3,5-Cl2 acts as an inverse agonist to downregulate pro-oncogenic and proendometriotic gene products, and as an agonist to enhance NR4A1/2/Sp1/Sp4-mediated CD71 transactivation. DIM-3,5-Cl2 induces ferroptosis via ROS formation, lipoperoxidation, MDA production, and reduced GPX4, SLC7A11 expression. DIM-3,5-Cl2 induces apoptosis via PARP and caspase-3 cleavage, reduced BCL-2 expression, and inhibits cancer cell viability. DIM-3,5-Cl2 can be used for the research of triple negative breast cancer, endometriosis, and colorectal cancer.

Dilopetine citrate is an inhibitor of substance P release. Dilopetine citrate dose-dependently reduces the vocalizing of isolated guinea pig pups. Dilopetine citrate shows good activity as an antidepressant.

Dihydro-α-ionone is a volatile compound found in the essential oil of Persicaria hydropiper L. leaves. The essential oil can inhibit α-glucosidase and α-amylase activities.

Dihydrogalanthamine hydrobromide is an acetylcholinesterase inhibitor. Dihydrogalanthamine hydrobromide can be used in research on neurological diseases such as sequelae of poliomyelitis and myasthenia gravis.

Diethyl benzylmalonate is a drug intermediate that can be used for the synthesis of central inhibitory agents.

Diclofop (Dichlorfop acid) is an acetyl-CoA carboxylase (ACC) inhibitor. Diclofop is also the major metabolite of the herbicide Diclofop-methyl. Diclofop exhibits antimalarial activity with an IC50 of 210 μM against P. falciparum.

Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid (Compound 5) is a cytotoxic pyrrolobenzodiazepine (PBD) dimer derivative. Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid exhibits moderate DNA alkylating activity. Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid can be used as the payload of ADC, thereby demonstrating strong antigen-dependent cytotoxicity.